Lantheus (LNTH) 10-Q 5 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 04, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	LNTH
Entity Registrant Name	LANTHEUS HOLDINGS, INC.
Entity Central Index Key	1,521,036
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		30,861,376

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenues	$ 73,314	$ 75,613	$ 148,137	$ 148,949
Cost of goods sold	40,647	44,554	79,701	87,829
Gross profit	32,667	31,059	68,436	61,120
Operating expenses
Sales and marketing expenses	9,229	9,402	18,301	18,900
General and administrative expenses	15,444	8,990	24,567	17,842
Research and development expenses	2,638	2,687	8,834	5,909
Total operating expenses	27,311	21,079	51,702	42,651
Operating income	5,356	9,980	16,734	18,469
Interest expense, net	(13,876)	(10,567)	(24,499)	(21,119)
Loss on extinguishment of debt	(15,528)		(15,528)
Other income (expense), net	800	(175)	417	(589)
Income (loss) before income taxes	(23,248)	(762)	(22,876)	(3,239)
Provision (benefit) for income taxes	1,175	874	1,172	(318)
Net loss	$ (24,423)	$ (1,636)	$ (24,048)	$ (2,921)
Net loss per common share:
Basic and diluted	$ (1.29)	$ (0.09)	$ (1.30)	$ (0.16)
Common shares:
Basic and diluted	18,898,003	18,080,944	18,489,451	18,080,256

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net loss	$ (24,423)	$ (1,636)	$ (24,048)	$ (2,921)
Foreign currency translation	(16)	603	(374)	332
Total comprehensive loss	$ (24,439)	$ (1,033)	$ (24,422)	$ (2,589)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 22,200	$ 19,739
Accounts receivable, net of allowance of $502 and $585	36,817	41,540
Inventory	15,396	15,582
Other current assets	4,577	4,374
Total current assets	78,990	81,235
Property, plant and equipment, net	92,867	96,014
Capitalized software development costs, net	2,099	2,421
Intangibles, net	24,099	27,191
Goodwill	15,714	15,714
Other long-term assets	19,781	20,578
Total assets	233,550	243,153
Current liabilities
Line of credit		8,000
Accounts payable	14,203	15,665
Accrued expenses and other liabilities	19,692	24,863
Current portion of long-term debt	3,650
Total current liabilities	37,545	48,528
Asset retirement obligation	7,861	7,435
Long-term debt, net	350,927	392,863
Other long-term liabilities	32,799	33,597
Total liabilities	$ 429,132	$ 482,423
Commitments and contingencies (See Note 15) Stockholders' deficit
Preferred stock ($0.01 par value, 25,000,000 shares authorized; no shares issued and outstanding)
Common stock ($0.01 par value, 250,000,000 shares authorized; 30,337,521 and 18,080,944 shares issued; 30,337,521 and 18,075,907 shares outstanding)	$ 303	$ 181
Treasury stock (no shares and 5,037 shares, at cost)		(106)
Additional paid-in capital	174,581	106,699
Accumulated deficit	(368,462)	(344,414)
Accumulated other comprehensive loss	(2,004)	(1,630)
Total stockholders' deficit	(195,582)	(239,270)
Total liabilities and stockholders' deficit	$ 233,550	$ 243,153

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 502	$ 585
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock , par value	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	30,337,521	18,080,944
Common stock, shares outstanding	30,337,521	18,075,907
Treasury stock, shares	0	5,037

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2013	$ (235,517)	$ 0	$ 181	$ (106)	$ 105,655	$ (340,853)	$ (394)
Balance, (in shares) at Dec. 31, 2013		0	18,078,725	(5,037)
Net share option exercise	13				13
Net share option exercise, shares			2,219
Net loss	(3,561)					(3,561)
Other comprehensive loss	(1,236)						(1,236)
Stock-based compensation	1,031				1,031
Balance at Dec. 31, 2014	(239,270)		$ 181	$ (106)	106,699	(344,414)	(1,630)
Balance, (in shares) at Dec. 31, 2014			18,080,944	(5,037)
Issuance of common stock from initial public offering, net of $6,362 issuance costs	$ 67,177		$ 122		67,055
Issuance of common stock from initial public offering, net of issuance costs, shares			12,256,577
Treasury stock retired				$ 106	(106)
Net share option exercise, shares	0
Treasury stock retired, shares				5,037
Net loss	$ (24,048)					(24,048)
Other comprehensive loss	(374)						(374)
Stock-based compensation	933				933
Balance at Jun. 30, 2015	$ (195,582)		$ 303		$ 174,581	$ (368,462)	$ (2,004)
Balance, (in shares) at Jun. 30, 2015			30,337,521

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Statement of Stockholders' Equity [Abstract]
Initial public offering, issuance costs	$ 6,362

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
Net loss	$ (24,048)	$ (2,921)
Adjustments to reconcile net loss to cash flow from operating activities
Depreciation and amortization	12,573	9,874
Provision for excess and obsolete inventory	467	890
Stock-based compensation	933	535
Deferred income taxes	(13)	(20)
Loss on extinguishment of debt	15,528
Other	1,470	256
Increase (decrease) in cash from operating assets and liabilities
Accounts receivable	4,258	(3,736)
Inventory	(474)	1,106
Other current assets	(368)	(3,469)
Accounts payable	108	(3,929)
Accrued expenses and other liabilities	(6,715)	(3,634)
Cash provided by (used in) operating activities	3,719	(5,048)
Cash flows from investing activities
Capital expenditures	(6,112)	(3,480)
Proceeds from sale of property, plant and equipment		227
Cash used in investing activities	(6,112)	(3,253)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering	73,539
Initial public offering costs	(5,255)
Proceeds from issuance of common stock		13
Proceeds from issuance of long-term debt	360,438
Payments of senior notes	(400,000)
Payment for call premium on senior notes	(9,752)
Payments on line of credit	(8,000)
Proceeds from line of credit		5,500
Payments for offering costs	(563)
Payments on note payable	(37)	(35)
Deferred financing costs	(5,315)	(84)
Cash provided by financing activities	5,055	5,394
Effect of foreign exchange rate on cash	(201)	351
Increase (decrease) in cash and cash equivalents	2,461	(2,556)
Cash and cash equivalents, beginning of period	19,739	18,578
Cash and cash equivalents, end of period	22,200	16,022
Supplemental disclosure of cash flow information
Interest paid	27,741	19,628
Income taxes paid, net	73	404
Noncash investing and financing activities
Property, plant and equipment included in accounts payable and accrued expenses and other liabilities	1,576	1,226
Initial public offering costs included in accounts payable and accrued expenses and other liabilities	1,107	$ 910
Deferred financing costs included in accrued expenses and other liabilities	$ 923

Business Overview

Business Overview	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	1. Business Overview Overview Holdings, a Delaware corporation, is the parent company of LMI, also a Delaware corporation. Holdings was formed for the purpose of acquiring the medical imaging business of Bristol-Myers Squibb, or BMS, which is now known as LMI. The Company develops, manufactures, sells and distributes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations and, in certain circumstances, wholesalers. The Company sells its products globally and has operations in the United States, Puerto Rico, Canada and Australia and distribution relationships in Europe, Asia Pacific and Latin America. The Company’s portfolio of 10 commercial products is diversified across a range of imaging modalities. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including the following: • DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle. • TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents. • Xenon Xe 133 Gas is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow. • Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name sestamibi, used with Single Photon Emission Computed Tomography, or SPECT, technology in myocardial perfusion imaging, or MPI, procedures that assess blood flow distribution to the heart. • Neurolite is an injectable, technetium-labeled imaging agent used with SPECT technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke. In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through commercial radiopharmacies owned or controlled by third parties. In Canada, Puerto Rico and Australia, the Company owns eight radiopharmacies and sells its own radiopharmaceuticals, as well as others, directly to end users. In Europe, Asia Pacific and Latin America, the Company utilizes distributor relationships to market, sell and distribute its products. Basis of Consolidation and Presentation The financial statements have been prepared in United States dollars, in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The condensed consolidated financial statements include the accounts of Holdings and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s financial statements for interim periods in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The information included in this quarterly report should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes included in the Company’s Prospectus dated June 24, 2015 and filed with the SEC on June 26, 2015, or the Prospectus. The Company’s accounting policies are described in the “Notes to Consolidated Financial Statements” in the Prospectus and updated, as necessary, in this quarterly report. There were no changes to the Company’s accounting policies since December 31, 2014 except that the Company has adopted a new accounting policy as discussed further below. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. Recent Events On June 25, 2015, in conjunction with its initial public offering, or IPO, the Company effected a corporate reorganization, whereby Lantheus MI Intermediate, Inc. (formerly the direct parent of LMI and the direct subsidiary of Holdings) was merged with and into Holdings, or the Merger. On June 30, 2015, the Company completed an IPO of its common stock at a price to the public of $6.00 per share. The Company’s common stock is now traded on the NASDAQ Global Select Market (NASDAQ) under the symbol “LNTH”. The Company issued and sold 12,256,577 shares of common stock in the IPO, including 1,423,243 shares that were offered and sold pursuant to the underwriters’ exercise in full of its overallotment option. The IPO raised proceeds to the Company of approximately $67.2 million, after deducting $6.4 million in underwriting discounts, commissions and related expenses. On June 30, 2015, the Company also entered into a $365.0 million senior secured term loan facility, or the Term Facility. The net proceeds of the Term Facility, together with the net proceeds from the IPO and the cash use of $10.9 million were used to repay in full the aggregate principal amount of LMI’s $400.0 million 9.750% Senior Notes due 2017, or the Notes, pay related premiums, interest and expenses and pay down the $8.0 million of outstanding borrowings under LMI’s $50.0 million revolving credit facility, or the Revolving Facility. The Company currently relies on Jubilant HollisterStier, or JHS, as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company has additional ongoing technology transfer activities at JHS for its Cardiolite product supply, which is currently manufactured by a single manufacturer. In addition, the Company has ongoing technology transfer activities at Pharmalucence for the manufacture and supply of DEFINITY, and the Company believes it will file for U.S. Food and Drug Administration, or FDA, approval to manufacture DEFINITY at Pharmalucence in 2015. The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company’s ability to maintain and profitably renew these contracts and relationships with these key customers and group purchasing organizations is an important aspect of the Company’s strategy. The Company’s written supply agreements with a major customer relating to TechneLite, Xenon, Neurolite, Cardiolite and certain other products expired in accordance with contract terms on December 31, 2014. Extended discussions with this customer have not yet resulted in new written supply agreements. Consequently, the Company is currently accepting and fulfilling product orders with this customer on a purchase order basis. Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives. During 2013 and 2014, the Company has utilized its revolving line of credit as a source of liquidity from time to time. Borrowing capacity under the Revolving Facility is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves, or the Borrowing Base. If the Company is not successful in achieving its forecasted operating results, the Company’s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company’s borrowing capacity. As of June 30, 2015, the aggregate Borrowing Base was approximately $38.8 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $29.9 million. The Company’s new Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the revolving line of credit may affect the Company’s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage, accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity. Based on the Company’s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company’s liquidity requirements for at least the next twelve months. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities, accrued expenses and stock-based compensation. Actual results could materially differ from those estimates or assumptions. Stock Split In conjunction with the Merger, the Company effected a 0.355872-for-1 reverse stock split for its common stock. Upon consummation of the Merger, the par value of the common stock changed from $0.001 to $0.01. Accordingly, all references to share and per share information in the condensed consolidated financial statements have been adjusted to reflect the stock split and new par value for all periods presented. Debt Issuance Costs In April 2015, the Financial Accounting Standards Board, or the FASB, issued ASU No. 2015-03, “Interest—Imputation of Interest (Topic 835): Simplifying the Presentation of Debt Issuance Costs,” or ASU 2015-03. Under the new ASU, debt issuance costs related to a recognized debt liability will be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability. As a result, the Company’s balance sheet will reflect a reclassification of unamortized debt issuance costs from other long-term assets to long-term debt, net. ASU 2015-03 is effective for interim and annual periods beginning after December 15, 2015, and early adoption is permitted. The Company has adopted this standard effective as of June 30, 2015 and applied the changes retrospectively to the prior periods presented. Adoption of this standard has resulted in the reclassification of $6.4 million from other long-term assets to long-term debt, net on the balance sheet at December 31, 2014. Unamortized debt issuance costs of $5.9 million are recorded as a reduction to long-term debt, net on the condensed consolidated balance sheets at June 30, 2015.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Revenue Recognition The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed and determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price. The best estimate of selling price reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement. Inventory Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. For the six months ended June 30, 2014, the Company expensed $1.3 million of such product costs in cost of goods sold relating to Neurolite that was manufactured by JHS. There was no significant product expensed for the six months ended June 30, 2015. At June 30, 2015 and December 31, 2014, the Company had no capitalized inventories associated with product that did not have regulatory approval. Goodwill Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. There were no events as of June 30, 2015 and December 31, 2014 that triggered an interim impairment test of goodwill.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014, and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points from active markets that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability. June 30, 2015 (in thousands) Total fair Quoted prices Significant other Significant Money market $ 1,558 $ 1,558 $ — $ — Certificates of deposit—restricted 83 — 83 — Total $ 1,641 $ 1,558 $ 83 $ — December 31, 2014 (in thousands) Total fair Quoted prices Significant other Significant Money market $ 2,737 $ 2,737 $ — $ — Certificates of deposit—restricted 89 — 89 — Total $ 2,826 $ 2,737 $ 89 $ — At both June 30, 2015 and December 31, 2014, the Company has a $0.1 million certificate of deposit which is collateral for a long-term lease and is included in other long-term assets on the condensed consolidated balance sheet. Certificates of deposit are classified within Level 2 of the fair value hierarchy, as these are not traded on the open market. At June 30, 2015, after giving effect to the closing of the IPO and the Term Facility, the repayment in full of the aggregate principal amount of $400.0 million Notes together with related premiums, interest and expenses and the pay down of $8.0 million of borrowings under the Revolving Facility, the Company had total cash and cash equivalents of $22.2 million, which included approximately $1.6 million of money market funds and $20.6 million of cash on-hand. At December 31, 2014, the Company had total cash and cash equivalents of $19.7 million, which included approximately $2.7 million of money market funds and $17.0 million of cash on-hand. The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, receivables, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The estimated fair value of the Company’s Term Facility at June 30, 2015, approximated its carrying value as the Company entered into the Term Facility at June 30, 2015. At December 31, 2014, the estimated fair value of the Senior Notes based on Level 2 inputs of recent market activity available to the Company was $384.0 million compared to the face value of $400.0 million.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	4. Income Taxes The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year in addition to discrete events which impact the interim period. The Company’s effective tax rate differs from the U.S. statutory rate principally due to the rate impact of uncertain tax positions, valuation allowance changes and state taxes. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective rate is determined. The Company’s tax provision was $1.2 million for the three and six months ended June 30, 2015, compared to a tax provision of $0.9 million and a benefit of $0.3 million for the three and six months ended June 30, 2014, respectively. In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb Company, or BMS, in 2008, the Company obtained a tax indemnification agreement with BMS related to certain tax obligations arising prior to the acquisition of the Company, for which the Company has the primary legal obligation. The tax indemnification receivable is recognized within other long-term assets. The changes in the tax indemnification asset are recognized within other expense, net in the condensed consolidated statement of operations. In accordance with the Company’s accounting policy, the change in the tax liability and penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within the tax provision. Accordingly, as these reserves change, adjustments are included in the tax provision while the offsetting adjustment is included in other expense, net. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there is no net effect on earnings related to these liabilities and no net cash outflows. On March 13, 2014, New York State, BMS, the Company and a relator entered into a Stipulation and Settlement Agreement and other related agreements, or collectively the Settlement Documents, to resolve an investigation by the Office of the Attorney General of New York State, claims relating to certain New York State and New York City tax matters and related claims under the New York False Claims Act. The claims at issue arose during the period from January 1, 2002 through December 31, 2006, which predated the acquisition of the medical imaging business from BMS in January 2008 and are subject to the tax indemnification agreement described above. Pursuant to the Settlement Documents, BMS paid (on behalf of itself and the Company) $6.3 million, and neither BMS nor the Company admitted any liability. The Company received a full release from New York State, New York City and the relator with respect to the claims at issue. During the six months ended June 30, 2015, BMS, on behalf of the Company, made payments totaling $1.9 million to a number of states in connection with state income tax settlements.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory	5. Inventory The Company includes within current assets the amount of inventory that is estimated to be utilized within twelve months. Inventory that will be utilized after twelve months is classified within other long-term assets. Inventory, classified in inventory or other long-term assets, consisted of the following: (in thousands) June 30, December 31, Raw materials $ 6,535 $ 6,043 Work in process 1,732 1,788 Finished goods 7,129 7,751 Inventory 15,396 15,582 Other long-term assets 1,156 1,156 Total $ 16,552 $ 16,738 At both June 30, 2015 and December 31, 2014, inventories reported as other long-term assets included $1.2 million of raw materials.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	6. Property, Plant and Equipment, net Property, plant and equipment consisted of the following: (in thousands) June 30, December 31, Land $ 14,950 $ 14,950 Buildings 68,296 67,571 Machinery, equipment and fixtures 63,536 65,179 Construction in progress 12,020 9,746 Accumulated depreciation (65,935 ) (61,432 ) Property, plant and equipment, net $ 92,867 $ 96,014 For the three and six months ended June 30, 2015, depreciation expense related to property, plant and equipment was $2.0 million and $7.7 million, respectively, as compared to $2.1 million and $4.4 million for the prior year comparative periods. Included within machinery, equipment and fixtures are spare parts of approximately $2.5 million at both June 30, 2015 and December 31, 2014. Spare parts include replacement parts relating to plant and equipment and are either recognized as an expense when consumed or re-classified and capitalized as part of the related plant and equipment and depreciated over a time period not exceeding the useful life of the related asset. Fixed assets dedicated to research and development, or R&D, activities, which were impacted by the March 2013 R&D strategic shift, have a carrying value of $4.8 million as of June 30, 2015. The Company believes these fixed assets will be utilized for either internally funded ongoing R&D activities or R&D activities funded by a strategic partner. If the Company is not successful in finding a strategic partner and there are no alternative uses for these fixed assets, then they could be subject to impairment in the future. Long-Lived Assets to Be Disposed of Other than by Sale In November 2014, the Company announced its plans to decommission certain long-lived assets associated with its R&D operations in the United States. The Company expected the decommissioning to begin in the second half of 2015. As a result, the Company revised its estimates of the remaining useful lives of the affected long-lived assets to seven months. During the second quarter of 2015, the Company halted its decommissioning plans until an indefinite date. As a result, the Company revised its estimates of the remaining useful lives of the affected long-lived assets back to its original remaining useful life effective April 1, 2015. This resulted in a decrease in depreciation expense of $3.7 million during the quarter ended June 30, 2015, as compared to the quarter ended March 31, 2015, and is included in R&D expenses in the condensed consolidated statement of operations. At June 30, 2015 and December 31, 2014, the net book value of these assets totaled $3.7 million and $7.4 million, respectively.

Asset Retirement Obligations

Asset Retirement Obligations	6 Months Ended
	Jun. 30, 2015
Asset Retirement Obligation Disclosure [Abstract]
Asset Retirement Obligations	7. Asset Retirement Obligations The Company considers the legal obligation to remediate its facilities upon a decommissioning of its radioactive related operations as an asset retirement obligation. The operations of the Company have radioactive production facilities at its North Billerica, Massachusetts and San Juan, Puerto Rico sites. The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of the North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond, which itself is currently secured by an $8.8 million unfunded Standby Letter of Credit provided to the third party issuer of the bond. The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. As of June 30, 2015, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.0 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying value of the related long-lived assets and depreciated over the asset’s useful life. The following is a reconciliation of the Company’s asset retirement obligations for the six months ended June 30, 2015: (in thousands) Balance at January 1, 2015 $ 7,435 Accretion expense 426 Balance at June 30, 2015 $ 7,861

Intangibles, Net

Intangibles, Net	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles, Net	8. Intangibles, net Intangibles, net consisted of the following: June 30, 2015 (in thousands) Cost Accumulated Net Amortization Trademarks $ 13,540 $ 6,025 $ 7,515 Straight-line Customer relationships 104,825 90,263 14,562 Accelerated Other patents 42,780 40,758 2,022 Straight-line $ 161,145 $ 137,046 $ 24,099 December 31, 2014 (in thousands) Cost Accumulated Net Amortization Trademarks $ 13,540 $ 5,116 $ 8,424 Straight-line Customer relationships 105,373 88,931 16,442 Accelerated Other patents 42,780 40,455 2,325 Straight-line $ 161,693 $ 134,502 $ 27,191 For the three and six months ended June 30, 2015, the Company recorded amortization expense for its intangible assets of $1.5 million and $3.0 million, respectively, as compared to $1.9 million and $3.8 million for the prior year comparative periods. Expected future amortization expense related to the intangible assets is as follows: (in thousands) Remainder of 2015 $ 2,987 2016 5,300 2017 3,492 2018 2,769 2019 1,897 2020 and thereafter 7,654 $ 24,099

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Accrued Expenses and Other Liabilities	9. Accrued Expenses and Other Liabilities Accrued expenses and other liabilities are comprised of the following: (in thousands) June 30, December 31, Compensation and benefits $ 9,399 $ 11,198 Accrued interest 90 4,994 Accrued professional fees 3,140 1,508 Research and development services 122 248 Freight, distribution and operations 2,988 3,069 Marketing expense 1,055 978 Accrued rebates, discounts and chargebacks 2,156 2,164 Other 742 704 $ 19,692 $ 24,863

Financing Arrangements

Financing Arrangements	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Financing Arrangements	10. Financing Arrangements Term Facility On June 30, 2015, the Company entered into a new $365.0 million seven-year Term Facility, which was issued net of a 1.25% discount of $4.6 million. The Company has a right to request an increase of the Term Facility in an aggregate amount up to $37.5 million subject to certain leverage ratios. The net proceeds of the Term Facility, together with the net proceeds of the IPO and cash on hand, were used to refinance in full the aggregate principal amount of the Notes and pay related premiums, interest and expenses. The term loans under the Term Facility bear interest, with pricing based from time to time at the Company’s election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%. Interest under term loans based on (i) the LIBOR rate is payable at the end of each interest period (as defined in our Term Facility) and (ii) the Base Rate is payable at the end of each quarter. The Company is permitted to voluntarily prepay the Term Facility, in whole or in part, with a premium applicable for the first six months of the Term Facility in connection with a repricing transaction. The Company is required to make quarterly payments, beginning on September 30, 2015, in an amount equal to a quarter of a percent (0.25%) per annum of the original principal amount of the Term Facility. The remaining unpaid principal amount of the Term Facility will be payable on the maturity date, or June 30, 2022. The Term Facility will require the Company to prepay outstanding term loans, subject to certain exceptions, with: • 100% of the net cash proceeds of all non-ordinary course sales or other dispositions of assets (including as a result of casualty or condemnation, subject to certain exceptions); the Company may reinvest or commit to reinvest certain of those proceeds in assets useful in our business within twelve months; • 100% of the net cash proceeds from issuances or incurrence of debt, other than proceeds from debt permitted under the Term Facility and Revolving Facility; • 50% (with two leverage-based stepdowns) of the Company’s excess cash flow; and • 50% of net payments from the Zurich insurance settlement (as defined therein). The foregoing mandatory prepayments will be applied to the scheduled installments of principal of the Term Facility in direct order of maturity. The Term Facility is guaranteed by the Company and Lantheus Real Estate, and obligations under the Term Facility are secured by substantially all the property and assets and all interests of the Company. The Company’s maturities of principal obligations under the Term Facility are as follows as of June 30, 2015: (in thousands) Remainder of 2015 $ 1,825 2016 3,650 2017 3,650 2018 3,650 2019 3,650 2020 and thereafter 348,575 Total debt 365,000 Unamortized debt discount (4,562 ) Unamortized debt issuance costs (5,861 ) Total 354,577 Less current portion (3,650 ) Total long-term debt $ 350,927 Term Facility Covenants The Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Term Facility requires the Company to be in quarterly compliance, measured on a trailing four quarter basis. The financial covenants are displayed in the table below: Term Facility Financial Covenants Period Total Net Leverage Ratio Q3 2015 to Q1 2016 6.25 to 1.00 Q2 2016 to Q4 2016 6.00 to 1.00 Q1 2017 to Q2 2017 5.50 to 1.00 Thereafter 5.00 to 1.00 The Term Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates. Financing Costs LMI incurred and capitalized approximately $5.9 million in debt issuance costs, consisting primarily of underwriting fees and expenses and legal fees in connection with the issuance of the Term Facility. Unamortized debt issuance costs associated with the Term Facility are recorded as a reduction to long-term debt on the condensed consolidated balance sheets. Debt issuance costs are being amortized over the life of the Term Facility, as appropriate, using the effective interest method and are included in interest expense in the accompanying condensed consolidated statements of operations. On June 30, 2015, LMI amended its existing Revolving Facility upon the closing of the Term Facility. The amendment extended the expiration date on the Revolving Facility and further modified certain definitions. In connection with the June 30, 2015 amendment, LMI incurred approximately $0.4 million in fees and expenses, which is included in other current assets on the condensed consolidated balance sheets. These fees are being amortized over the remaining life of the Revolving Facility using the straight-line method and are included in interest expense in the accompanying consolidated statements of operations. Senior Notes LMI had $400.0 million in aggregate principal amount of the Notes outstanding. The interest on the Notes was at a rate of 9.750% per year, payable on May 15 and November 15 of each year. The net proceeds of the Term Facility, together with the net proceeds of the IPO and cash on hand, were used to refinance in full the aggregate principal amount of the Notes and pay related premiums, interest and expenses. The Company satisfied and discharged its obligations under the Notes as of June 30, 2015. The notes and accrued interest were redeemed in full on July 30, 2015. The Company recorded a loss on extinguishment of debt totaling $15.5 million, which included a redemption premium of $9.7 million and a $5.8 million write-off of unamortized debt issuance costs associated with the Senior Notes. As of June 30, 2015, the Company also paid the accrued interest to the redemption date totaling $3.3 million, which is included in interest expense on the condensed consolidated statement of operations. Revolving Line of Credit At June 30, 2015, LMI has a Revolving Facility with an aggregate principal amount not to exceed $50.0 million. The loans under the Revolving Facility bear interest subject to a pricing grid based on average historical excess availability, with pricing based from time to time at the election of LMI at (i) LIBOR plus a spread ranging from 2.00% or (ii) the Reference Rate (as defined in the agreement) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020. As of June 30, 2015 and December 31, 2014, LMI has an unfunded Standby Letter of Credit for up to $8.8 million. The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires on February 5, 2016, which will automatically renew for a one year period at each anniversary date, unless LMI elects not to renew in writing within 60 days prior to that expiration. The Revolving Facility contains a number of affirmative, negative, reporting and financial covenants, as well as a financial covenant during trigger periods in the form of a consolidated fixed charge coverage ratio of not less than 1:00:1:00. Upon an event of default, the lender has the right to declare the loans and other obligations outstanding immediately due and payable and all commitments immediately terminated or reduced, and the lender may, after such events of default, require LMI to make deposits with respect to any outstanding letters of credit in an amount equal to 105% of the greatest amount for which such letter of credit may be drawn. The Revolving Facility is guaranteed by Holdings and Lantheus Real Estate and is secured by a pledge of substantially all of the assets of each of the loan parties including accounts receivable, inventory and machinery and equipment. Borrowing capacity is determined by reference to a Borrowing Base, which is based on a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves. As of June 30, 2015, the aggregate Borrowing Base was approximately $38.8 million, which was reduced an outstanding $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $29.9 million.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholders' Equity	11. Stockholders’ Equity As of June 30, 2015, the authorized capital stock of the Company consisted of 250,000,000 shares of common stock, par value $0.01 per share, and 25,000,000 shares of preferred stock, par value $0.01 per share. The common stockholders are entitled to one vote per share and will share equally on a per share basis in any dividend declared by the Board of Directors, subject to any preferential rights of the holders of any outstanding preferred stock.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	12. Stock-Based Compensation As of June 24, 2015, the Company adopted the 2015 Equity Incentive Plan, or the 2015 Plan. The Company’s employees are eligible to receive awards under the 2015 Plan. The 2015 Plan is administered by the Board of Directors and permits the granting of nonqualified stock options, stock appreciation rights, or SARs, restricted stock, restricted stock units and dividend equivalent rights (“DERs”) to employees, officers, directors and consultants of the Company. The Board of Directors may, at its sole discretion, grant DERs with respect to any award and is treated as a separate award. The number of shares authorized for issuance under the 2015 Plan is 2,190,320. Option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Time based option awards vest based on time, typically four years, and performance based option awards vest based on the performance criteria specified in the grant. All option awards have a ten-year contractual term. The Company recognizes compensation costs for its time based awards on a straight-line basis equal to the vesting period. The compensation cost for performance based awards is recognized on a graded vesting basis, based on the probability of achieving the performance targets over the requisite service period for the entire award. The fair value of each option award is estimated on the date of grant using a Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatilities are based on the historic volatility of a selected peer group. Expected dividends represent the dividends expected to be issued at the date of grant. The expected term of options represents the period of time that options granted are expected to be outstanding. The risk-free interest rate assumption is the U.S. Treasury rate at the date of the grant which most closely resembles the expected life of the options. The Company uses the following Black-Scholes inputs to determine the fair value of new stock option grants. Three Months Six Months 2015 2014 2015 2014 Expected volatility 26 - 28 % 33 - 35 % 26 – 32 % 33 - 35 % Expected dividends — — — — Expected life (in years) 4.1 – 6.0 5.5 – 6.3 4.1 – 6.3 5.5 – 6.3 Risk-free interest rate 1.3 – 1.9 % 1.6 – 1.9 % 1.3 – 1.9 % 1.5 – 1.9 % A summary of option activity for 2015 is presented below: Time Based Performance Total Weighted Weighted Aggregate Outstanding at January 1, 2015 1,146,509 384,601 1,531,110 $ 13.57 6.4 $ 3,979,000 Options granted 274,481 — 274,481 12.24 Options cancelled (24,444 ) (3,904 ) (28,348 ) 21.48 Options exercised — — — — Options forfeited or expired (45,509 ) (54,769 ) (100,278 ) 19.76 Outstanding at June 30, 2015 1,351,037 325,928 1,676,965 12.84 5.7 $ 391,000 Vested and expected to vest at June 30, 2015 1,286,400 311,649 1,598,049 12.18 5.6 $ 383,000 Exercisable at June 30, 2015 714,180 209,257 923,437 10.60 4.5 $ 333,000 The weighted average grant-date fair value of options granted during the three and six months ended June 30, 2015 was $0.99 and $1.42, respectively, as compared to $5.65 and $5.84 for the prior year comparative periods. A summary of restricted stock awards activity for 2015 is presented below: Time Based Weighted Average Grant Issued and unvested at January 1, 2015 — $ — Granted 479,708 8.34 Vested — — Forfeited (2,846 ) 8.52 Issued and unvested at June 30, 2015 476,862 $ 8.34 Stock-based compensation expense for both time based and performance based stock options and restricted stock awards were recognized in the condensed consolidated statements of operations as follows: Three Months Six Months (in thousands) 2015 2014 2015 2014 Cost of goods sold $ 52 $ 31 $ 51 $ 72 General and administrative 465 154 679 323 Sales and marketing 79 37 115 81 Research and development 60 29 88 59 Total stock-based compensation expense $ 656 $ 251 $ 933 $ 535

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive. Three Months Ended Six Months Ended (in thousands, except share and per share amounts) 2015 2014 2015 2014 Net loss $ (24,423 ) $ (1,636 ) $ (24,048 ) $ (2,921 ) Basic and diluted weighted average common shares outstanding 18,898,003 18,080,944 18,489,451 18,080,256 Basic and diluted loss per common share $ (1.29 ) $ (0.09 ) $ (1.30 ) $ (0.16 ) The weighted average number of common shares for the three and six months ended June 30, 2015 and 2014, did not include 2,153,827 and 1,377,523 options and unvested restricted stock, respectively, because of their antidilutive effect.

Other Expense, Net

Other Expense, Net	6 Months Ended
	Jun. 30, 2015
Other Income and Expenses [Abstract]
Other Expense, Net	14. Other Expense, net Three Months Six Months (in thousands) 2015 2014 2015 2014 Foreign currency (losses) gains $ 18 $ (154 ) $ (360 ) $ (392 ) Tax indemnification (loss) income 781 (22 ) 777 (197 ) Other income 1 1 — — Total other income (expense), net $ 800 $ (175 ) $ 417 $ (589 )

Legal Proceedings and Contingen

Legal Proceedings and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	15. Legal Proceedings and Contingencies From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. As of June 30, 2015, the Company had no material ongoing litigation in which the Company was a defendant or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business. On December 16, 2010, LMI filed suit against one of its insurance carriers seeking to recover business interruption losses associated with the NRU reactor shutdown and the ensuing global Moly supply shortage. The claim is the result of the shutdown of the NRU reactor in Chalk River, Ontario. The NRU reactor was off-line from May 2009 until August 2010. The defendant answered the complaint on January 21, 2011, denying substantially all of the allegations, presenting certain defenses and requesting dismissal of the case with costs and disbursements. Discovery, including international discovery and related motion practice, went on for more than three years. The defendant filed a motion for summary judgment on July 14, 2014. The Company filed a memorandum of law in opposition to defendant’s motion for summary judgment on August 25, 2014. The defendant filed a reply memorandum of law in further support of its motion for summary judgment on September 15, 2014. Expert witness discovery was completed on October 31, 2014. On March 25, 2015, the United States District Court for the Southern District of New York granted defendant’s motion for summary judgment. On May 22, 2015, the Company filed a notice of appeal of the District Court decision with the United States Court of Appeals for the Second Circuit. The Company cannot be certain when, if ever, it will be able to recover for business interruption losses related to this matter and in what amount, if any.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions Avista, the Company’s majority shareholder, provided certain advisory services to the Company pursuant to an advisory services and monitoring agreement. The Company was required to pay an annual fee of $1.0 million and other reasonable and customary advisory fees, as applicable, paid on a quarterly basis. The initial term of the agreement was seven years. On June 25, 2015, the Company exercised its right to terminate its advisory services and monitoring agreement with Avista. In connection with such termination, the Company has paid Avista Capital Holdings, L.P. an aggregate termination fee of $6.5 million, which is included in general and administrative expenses in the condensed consolidated statement of operations. During the three and six months ended June 30, 2015, the Company incurred costs associated with this agreement totaling $6.8 million and $7.0 million, respectively, as compared to $0.3 million and $0.5 million for the prior year comparative periods. At December 31, 2014, $10,000 was included in accrued expenses. There were no amounts outstanding as of June 30, 2015. The Company purchases inventory supplies from VWR Scientific, or VWR. Avista and certain of its affiliates are principal owners of both VWR and the Company. During each of the three and six months ended June 30, 2015, the Company made purchases of $44,000 and $115,000, respectively, as compared to $74,000 and $134,000 for the prior year comparative periods. At June 30, 2015 and December 31, 2014, $1,000 and $21,000, respectively, was included in accounts payable and accrued expenses. The Company retains Marsh for insurance brokering and risk management. Donald Bailey, brother of the Company’s President and Chief Executive Officer, Jeffrey Bailey, is head of sales for Marsh’s U.S. and Canada division. During each of the six months ended June 30, 2015 and 2014, the Company paid Marsh $0.1 million. At both June 30, 2015 and December 31, 2014, a prepaid amount of $43,000 was included in other current assets.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment Information	17. Segment Information The Company reports two operating segments, U.S. and International, based on geographic customer base. The results of these operating segments are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s segments derive revenues through the manufacturing, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. The U.S. segment comprises 79.6% and 80.4% of consolidated revenues for the three and six months ended June 30, 2015 as compared to 77.5% for the prior year comparative periods and 89.8% and 90.1% of consolidated assets at June 30, 2015 and December 31, 2014, respectively. All goodwill has been allocated to the U.S. operating segment. Selected information for each business segment are as follows (in thousands): Three Months Ended Six Months Ended 2015 2014 2015 2014 Revenues U.S. $ 64,689 $ 62,981 $ 130,477 $ 124,368 International 14,936 17,045 29,092 33,570 Total revenue, including inter-segment 79,625 80,026 159,569 157,938 Less inter-segment revenue (6,311 ) (4,413 ) (11,432 ) (8,989 ) $ 73,314 $ 75,613 $ 148,137 $ 148,949 Revenues from external customers U.S. $ 58,378 $ 58,568 $ 119,045 $ 115,379 International 14,936 17,045 29,092 33,570 $ 73,314 $ 75,613 $ 148,137 $ 148,949 Operating income U.S. $ 3,442 $ 8,417 $ 16,121 $ 15,437 International 2,059 1,345 585 2,644 Total operating income (loss), including inter-segment 5,501 9,762 16,706 18,081 Inter-segment operating income (loss) (145 ) 218 28 388 Operating income 5,356 9,980 16,734 18,469 Interest expense, net (13,876 ) (10,567 ) (24,499 ) (21,119 ) Loss on extinguishment of debt (15,528 ) — (15,528 ) — Other income (expense), net 800 (175 ) 417 (589 ) Loss before income taxes $ (23,248 ) $ (762 ) $ (22,876 ) $ (3,239 ) June 30, December 31, Total assets U.S. $ 209,665 $ 219,129 International 23,885 24,024 $ 233,550 $ 243,153

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed and determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price. The best estimate of selling price reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.
Inventory	Inventory Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. For the six months ended June 30, 2014, the Company expensed $1.3 million of such product costs in cost of goods sold relating to Neurolite that was manufactured by JHS. There was no significant product expensed for the six months ended June 30, 2015. At June 30, 2015 and December 31, 2014, the Company had no capitalized inventories associated with product that did not have regulatory approval.
Goodwill	Goodwill Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. There were no events as of June 30, 2015 and December 31, 2014 that triggered an interim impairment test of goodwill.

Fair Value of Financial Instr27

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis	The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014, and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points from active markets that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability. June 30, 2015 (in thousands) Total fair Quoted prices Significant other Significant Money market $ 1,558 $ 1,558 $ — $ — Certificates of deposit—restricted 83 — 83 — Total $ 1,641 $ 1,558 $ 83 $ — December 31, 2014 (in thousands) Total fair Quoted prices Significant other Significant Money market $ 2,737 $ 2,737 $ — $ — Certificates of deposit—restricted 89 — 89 — Total $ 2,826 $ 2,737 $ 89 $ —

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Classified in Inventory or Other Long-Term Assets	Inventory, classified in inventory or other long-term assets, consisted of the following: (in thousands) June 30, December 31, Raw materials $ 6,535 $ 6,043 Work in process 1,732 1,788 Finished goods 7,129 7,751 Inventory 15,396 15,582 Other long-term assets 1,156 1,156 Total $ 16,552 $ 16,738

Property, Plant and Equipment29

Property, Plant and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, plant and equipment consisted of the following: (in thousands) June 30, December 31, Land $ 14,950 $ 14,950 Buildings 68,296 67,571 Machinery, equipment and fixtures 63,536 65,179 Construction in progress 12,020 9,746 Accumulated depreciation (65,935 ) (61,432 ) Property, plant and equipment, net $ 92,867 $ 96,014

Asset Retirement Obligations (T

Asset Retirement Obligations (Tables)	6 Months Ended
	Jun. 30, 2015
Asset Retirement Obligation Disclosure [Abstract]
Schedule of Reconciliation of Company's Asset Retirement Obligations	The following is a reconciliation of the Company’s asset retirement obligations for the six months ended June 30, 2015: (in thousands) Balance at January 1, 2015 $ 7,435 Accretion expense 426 Balance at June 30, 2015 $ 7,861

Intangibles, Net (Tables)

Intangibles, Net (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangibles, Net	Intangibles, net consisted of the following: June 30, 2015 (in thousands) Cost Accumulated Net Amortization Trademarks $ 13,540 $ 6,025 $ 7,515 Straight-line Customer relationships 104,825 90,263 14,562 Accelerated Other patents 42,780 40,758 2,022 Straight-line $ 161,145 $ 137,046 $ 24,099 December 31, 2014 (in thousands) Cost Accumulated Net Amortization Trademarks $ 13,540 $ 5,116 $ 8,424 Straight-line Customer relationships 105,373 88,931 16,442 Accelerated Other patents 42,780 40,455 2,325 Straight-line $ 161,693 $ 134,502 $ 27,191
Schedule of Expected Future Amortization Expense Related to Intangible Assets	Expected future amortization expense related to the intangible assets is as follows: (in thousands) Remainder of 2015 $ 2,987 2016 5,300 2017 3,492 2018 2,769 2019 1,897 2020 and thereafter 7,654 $ 24,099

Accrued Expenses and Other Li32

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities are comprised of the following: (in thousands) June 30, December 31, Compensation and benefits $ 9,399 $ 11,198 Accrued interest 90 4,994 Accrued professional fees 3,140 1,508 Research and development services 122 248 Freight, distribution and operations 2,988 3,069 Marketing expense 1,055 978 Accrued rebates, discounts and chargebacks 2,156 2,164 Other 742 704 $ 19,692 $ 24,863

Financing Arrangements (Tables)

Financing Arrangements (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule of Maturities of Principal Obligations Under Term Facility	The Company’s maturities of principal obligations under the Term Facility are as follows as of June 30, 2015: (in thousands) Remainder of 2015 $ 1,825 2016 3,650 2017 3,650 2018 3,650 2019 3,650 2020 and thereafter 348,575 Total debt 365,000 Unamortized debt discount (4,562 ) Unamortized debt issuance costs (5,861 ) Total 354,577 Less current portion (3,650 ) Total long-term debt $ 350,927
Schedule of Term Facility Financial Covenants	The financial covenants are displayed in the table below: Term Facility Financial Covenants Period Total Net Leverage Ratio Q3 2015 to Q1 2016 6.25 to 1.00 Q2 2016 to Q4 2016 6.00 to 1.00 Q1 2017 to Q2 2017 5.50 to 1.00 Thereafter 5.00 to 1.00

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions used for Estimating Fair Value of Each Option Award on Date of Grant using Black-Scholes Valuation Model	The Company uses the following Black-Scholes inputs to determine the fair value of new stock option grants. Three Months Six Months 2015 2014 2015 2014 Expected volatility 26 - 28 % 33 - 35 % 26 – 32 % 33 - 35 % Expected dividends — — — — Expected life (in years) 4.1 – 6.0 5.5 – 6.3 4.1 – 6.3 5.5 – 6.3 Risk-free interest rate 1.3 – 1.9 % 1.6 – 1.9 % 1.3 – 1.9 % 1.5 – 1.9 %
Schedule of Option Activity	A summary of option activity for 2015 is presented below: Time Based Performance Total Weighted Weighted Aggregate Outstanding at January 1, 2015 1,146,509 384,601 1,531,110 $ 13.57 6.4 $ 3,979,000 Options granted 274,481 — 274,481 12.24 Options cancelled (24,444 ) (3,904 ) (28,348 ) 21.48 Options exercised — — — — Options forfeited or expired (45,509 ) (54,769 ) (100,278 ) 19.76 Outstanding at June 30, 2015 1,351,037 325,928 1,676,965 12.84 5.7 $ 391,000 Vested and expected to vest at June 30, 2015 1,286,400 311,649 1,598,049 12.18 5.6 $ 383,000 Exercisable at June 30, 2015 714,180 209,257 923,437 10.60 4.5 $ 333,000
Summary of Restricted Stock Awards Activity	A summary of restricted stock awards activity for 2015 is presented below: Time Based Weighted Average Grant Issued and unvested at January 1, 2015 — $ — Granted 479,708 8.34 Vested — — Forfeited (2,846 ) 8.52 Issued and unvested at June 30, 2015 476,862 $ 8.34
Schedule of Stock-Based Compensation Expense Recognized	Stock-based compensation expense for both time based and performance based stock options and restricted stock awards were recognized in the condensed consolidated statements of operations as follows: Three Months Six Months (in thousands) 2015 2014 2015 2014 Cost of goods sold $ 52 $ 31 $ 51 $ 72 General and administrative 465 154 679 323 Sales and marketing 79 37 115 81 Research and development 60 29 88 59 Total stock-based compensation expense $ 656 $ 251 $ 933 $ 535

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Summary of Net Loss Per Share	During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive. Three Months Ended Six Months Ended (in thousands, except share and per share amounts) 2015 2014 2015 2014 Net loss $ (24,423 ) $ (1,636 ) $ (24,048 ) $ (2,921 ) Basic and diluted weighted average common shares outstanding 18,898,003 18,080,944 18,489,451 18,080,256 Basic and diluted loss per common share $ (1.29 ) $ (0.09 ) $ (1.30 ) $ (0.16 )

Other Expense, Net (Tables)

Other Expense, Net (Tables)	6 Months Ended
	Jun. 30, 2015
Other Income and Expenses [Abstract]
Schedule of Other Expense, Net	Three Months Six Months (in thousands) 2015 2014 2015 2014 Foreign currency (losses) gains $ 18 $ (154 ) $ (360 ) $ (392 ) Tax indemnification (loss) income 781 (22 ) 777 (197 ) Other income 1 1 — — Total other income (expense), net $ 800 $ (175 ) $ 417 $ (589 )

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of Selected Information for Each Business Segment	Selected information for each business segment are as follows (in thousands): Three Months Ended Six Months Ended 2015 2014 2015 2014 Revenues U.S. $ 64,689 $ 62,981 $ 130,477 $ 124,368 International 14,936 17,045 29,092 33,570 Total revenue, including inter-segment 79,625 80,026 159,569 157,938 Less inter-segment revenue (6,311 ) (4,413 ) (11,432 ) (8,989 ) $ 73,314 $ 75,613 $ 148,137 $ 148,949 Revenues from external customers U.S. $ 58,378 $ 58,568 $ 119,045 $ 115,379 International 14,936 17,045 29,092 33,570 $ 73,314 $ 75,613 $ 148,137 $ 148,949 Operating income U.S. $ 3,442 $ 8,417 $ 16,121 $ 15,437 International 2,059 1,345 585 2,644 Total operating income (loss), including inter-segment 5,501 9,762 16,706 18,081 Inter-segment operating income (loss) (145 ) 218 28 388 Operating income 5,356 9,980 16,734 18,469 Interest expense, net (13,876 ) (10,567 ) (24,499 ) (21,119 ) Loss on extinguishment of debt (15,528 ) — (15,528 ) — Other income (expense), net 800 (175 ) 417 (589 ) Loss before income taxes $ (23,248 ) $ (762 ) $ (22,876 ) $ (3,239 ) June 30, December 31, Total assets U.S. $ 209,665 $ 219,129 International 23,885 24,024 $ 233,550 $ 243,153

Business Overview - Additional

Business Overview - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2015USD ($)Item$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of commercial products | Item	10
Number of radiopharmacies owned | Item	8
Common stock, number of shares issued and sold | shares	30,337,521	18,080,944
Proceeds from issuance of common stock in initial public offering, net of issuance costs	$ 73,539,000
Term loan facility, Face amount		$ 400,000,000
Net proceeds of the Term Facility, IPO and cash	$ 10,900,000
Common stock, stock split ratio	0.355872
Common stock, par value | $ / shares	$ 0.01	$ 0.01
Amount reclassified from other noncurrent assets to long-term debt		$ 6,400,000
Unamortized debt issuance costs	$ 5,900,000
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, number of shares issued and sold | shares	12,256,577
Proceeds from issuance of common stock in initial public offering, net of issuance costs	$ 67,200,000
Underwriting discounts, commissions and related expenses	$ 6,400,000
Over-Allotment Option [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, number of shares issued and sold | shares	1,423,243
Previously Reported [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, par value | $ / shares	$ 0.001
Common Stock [Member] | IPO [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shares issued, price per share | $ / shares	$ 6
Senior Secured Term Loan Facility [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Term loan facility, Face amount	$ 365,000,000
Aggregate principal amount outstanding	365,000,000
Unamortized debt issuance costs	5,861,000
Senior Notes [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Aggregate principal amount outstanding	$ 400,000,000
Notes interest rate	9.75%
Unamortized debt issuance costs	$ 5,800,000
Senior Notes Due 2017 [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Notes interest rate	9.75%
Revolving Line of Credit [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Outstanding borrowing	$ 8,000,000
Borrowing base	38,800,000
Unfunded standby letter of credit outstanding	8,800,000	$ 8,800,000
Available borrowing capacity	29,900,000
Accrued interest	100,000
LMI [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Outstanding borrowing	$ 50,000,000

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Schedule Of Accounting Policies [Line Items]
Cost of goods sold	$ 40,647,000	$ 44,554,000	$ 79,701,000	$ 87,829,000
Capitalized inventories			0		$ 0
Neurolite [Member]
Schedule Of Accounting Policies [Line Items]
Cost of goods sold			$ 0	$ 1,300,000

Fair Value of Financial Instr40

Fair Value of Financial Instruments - Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Recurring Basis [Member] - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 1,641	$ 2,826
Money Market [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, fair value	1,558	2,737
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	83	89
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	1,558	2,737
Quoted Prices in Active Markets (Level 1) [Member] | Money Market [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, fair value	1,558	2,737
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	83	89
Significant Other Observable Inputs (Level 2) [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	$ 83	$ 89

Fair Value of Financial Instr41

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, carrying value	$ 22,200	$ 19,739	$ 16,022	$ 18,578
Face value of debt		400,000
Money Market [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, carrying value	1,600	2,700
Cash-On-Hand [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, carrying value	20,600	17,000
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments, noncurrent	100	100
Seven Year Term Facility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate principal amount outstanding	365,000
Revolving Line of Credit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Outstanding borrowing	8,000
IPO [Member] | Seven Year Term Facility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate principal amount outstanding	$ 400,000
Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value of the debt		$ 384,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Taxes And Tax Related [Line Items]
Provision (benefit) for income taxes	$ 1,175,000	$ 874,000	$ 1,172,000	$ (318,000)
BMS [Member]
Income Taxes And Tax Related [Line Items]
Net effect on earnings related to deferred tax liabilities	$ 0		0
Net effect on cash flow related to deferred tax liabilities			0
Settlement expense			6,300,000
Payments made on behalf of the company to a number of states in connection with state income tax settlements			$ 1,900,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory, Classified in Inventory or Other Long-term Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 6,535	$ 6,043
Work in process	1,732	1,788
Finished goods	7,129	7,751
Inventory	15,396	15,582
Other long-term assets	1,156	1,156
Total	$ 16,552	$ 16,738

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Non-current raw materials	$ 1.2	$ 1.2

Property, Plant and Equipment45

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Accumulated depreciation	$ (65,935)	$ (61,432)
Property, plant and equipment, net	92,867	96,014
Land [Member]
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	14,950	14,950
Buildings [Member]
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	68,296	67,571
Machinery, Equipment and Fixtures [Member]
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	63,536	65,179
Construction in Progress [Member]
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	$ 12,020	$ 9,746

Property, Plant and Equipment46

Property, Plant and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 20, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 2,000	$ 2,100	$ 7,700	$ 4,400
Property, plant and equipment, net	92,867		92,867			$ 96,014
Net book value of assets					$ 3,700	7,400
Spare Parts [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,500		2,500			$ 2,500
Fixed Assets Dedicated to R&D Activities [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 4,800		4,800
Research and Development [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense			$ 3,700

Asset Retirement Obligations -

Asset Retirement Obligations - Additional Information (Detail) - Jun. 30, 2015 - USD ($) $ in Millions	Total
Asset Retirement Obligation Disclosure [Abstract]
Financial assurance in form of surety bond	$ 28.2
Unfunded standby letter of credit	8.8
Asset retirement obligation liabilities expected, present value	$ 26

Asset Retirement Obligations 48

Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Asset Retirement Obligation Disclosure [Abstract]
Balance at the beginning of the period	$ 7,435
Accretion expense	426
Balance at the ending of the period	$ 7,861

Intangibles, Net - Schedule of

Intangibles, Net - Schedule of Intangibles, Net (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Cost	$ 161,145	$ 161,693
Accumulated amortization	137,046	134,502
Net	24,099	27,191
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	13,540	13,540
Accumulated amortization	6,025	5,116
Net	$ 7,515	8,424
Amortization Method	Straight-line
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	$ 104,825	105,373
Accumulated amortization	90,263	88,931
Net	$ 14,562	16,442
Amortization Method	Accelerated
Other Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	$ 42,780	42,780
Accumulated amortization	40,758	40,455
Net	$ 2,022	$ 2,325
Amortization Method	Straight-line

Intangibles, Net - Additional I

Intangibles, Net - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Amortization expense	$ 1.5	$ 1.9	$ 3	$ 3.8

Intangibles, Net - Schedule o51

Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Intangible Liability Disclosure [Abstract]
Remainder of 2015	$ 2,987
2,016	5,300
2,017	3,492
2,018	2,769
2,019	1,897
2020 and thereafter	7,654
Net	$ 24,099	$ 27,191

Accrued Expenses and Other Li52

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Compensation and benefits	$ 9,399	$ 11,198
Accrued interest	90	4,994
Accrued professional fees	3,140	1,508
Research and development services	122	248
Freight, distribution and operations	2,988	3,069
Marketing expense	1,055	978
Accrued rebates, discounts and chargebacks	2,156	2,164
Other	742	704
Accrued expenses	$ 19,692	$ 24,863

Financing Arrangements - Additi

Financing Arrangements - Additional Information (Detail)	3 Months Ended	6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Debt issuance costs		$ 5,315,000	$ 84,000
Loss on extinguishment of debt	$ (15,528,000)	(15,528,000)
Unamortized debt issuance costs	5,900,000	5,900,000
Accrued interest paid up to redemption date		$ 3,300,000
Consolidated fixed charge coverage ratio to be maintained		1
Deposits to be made in case of default equaling, percentage of greatest amount of letter of credit drawn		105.00%
LMI [Member]
Debt Instrument [Line Items]
Debt issuance costs		$ 5,900,000
Fees and expenses incurred in connection with amendment		400,000
Senior Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount outstanding	$ 400,000,000	$ 400,000,000
Maturity date of term facility		Jun. 30, 2015
Notes interest rate	9.75%	9.75%
Notes payment term, description		The interest on the Notes was at a rate of 9.750% per year, payable on May 15 and November 15 of each year.
Loss on extinguishment of debt		$ 15,500,000
Redemption premium		9,700,000
Unamortized debt issuance costs	$ 5,800,000	5,800,000
Seven Year Term Facility [Member]
Debt Instrument [Line Items]
Aggregate principal amount outstanding	$ 365,000,000	$ 365,000,000
Debt instrument discount percentage	1.25%	1.25%
Debt instrument discount amount	$ 4,600,000	$ 4,600,000
Increase in aggregate amount		$ 37,500,000
Description of variable rate basis		The term loans under the Term Facility bear interest, with pricing based from time to time at the Company's election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%.
Prepayment terms		The Company is permitted to voluntarily prepay the Term Facility, in whole or in part, with a premium applicable for the first six months of the Term Facility in connection with a repricing transaction.
Percentage of principal amount required to be paid quarterly		(0.25%)
Maturity date of term facility		Jun. 30, 2022
Percentage of net cash proceeds of all non-ordinary course sales or other dispositions of assets		100.00%
Percentage of net cash proceeds from issuances or incurrence of debt		100.00%
Percentage of excess cash flow	50.00%	50.00%
Seven Year Term Facility [Member] | Zurich Insurance Settlement [Member]
Debt Instrument [Line Items]
Percentage of net payments from insurance settlement		50.00%
Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Credit facility expiration date		Feb. 5, 2016
Unfunded standby letter of credit outstanding	$ 8,800,000	$ 8,800,000		$ 8,800,000
Renewal period of unfunded standby letter of credit		1 year
Period required for non renewal notification of debt instrument		60 days
Unfunded standby letter of credit payment term		The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00%
Borrowing base	38,800,000	$ 38,800,000
Available borrowing capacity	29,900,000	29,900,000
Accrued interest		$ 100,000
Revolving Line of Credit [Member] | LMI [Member]
Debt Instrument [Line Items]
Description of variable rate basis		The loans under the Revolving Facility bear interest subject to a pricing grid based on average historical excess availability, with pricing based from time to time at the election of LMI at (i) LIBOR plus a spread ranging from 2.00% or (ii) the Reference Rate (as defined in the agreement) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375%
Unused line of credit fee (as a percent)		0.375%
Maximum borrowing capacity	$ 50,000,000	$ 50,000,000
Credit facility expiration date		Jun. 30, 2020
LIBOR [Member] | Seven Year Term Facility [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		6.00%
LIBOR [Member] | Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		2.00%
LIBOR [Member] | Revolving Line of Credit [Member] | LMI [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		2.00%
Reference Rate [Member] | Seven Year Term Facility [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		5.00%
Reference Rate [Member] | Revolving Line of Credit [Member] | LMI [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		1.00%
Interest Rate Floor [Member] | Seven Year Term Facility [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		1.00%

Financing Arrangements - Schedu

Financing Arrangements - Schedule of Maturities of Principal Obligations Under Term Facility (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Unamortized debt issuance costs	$ (5,900)
Less current portion	(3,650)
Total long-term debt	350,927	$ 392,863
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Remainder of 2015	1,825
2,016	3,650
2,017	3,650
2,018	3,650
2,019	3,650
2020 and thereafter	348,575
Total debt	365,000
Unamortized debt discount	(4,562)
Unamortized debt issuance costs	(5,861)
Total	354,577
Total	354,577
Less current portion	(3,650)
Total long-term debt	$ 350,927

Financing Arrangement - Schedul

Financing Arrangement - Schedule of Term Facility Financial Covenants (Detail) - Term Facility Financial Covenants [Member]	6 Months Ended
	Jun. 30, 2015
Q3 2015 to Q1 2016 [Member] | Maximum [Member]
Quarterly Results Of Operations [Line Items]
Total Net Leverage Ratio	6.25
Q3 2015 to Q1 2016 [Member] | Minimum [Member]
Quarterly Results Of Operations [Line Items]
Total Net Leverage Ratio	1
Q2 2016 to Q4 2016 [Member] | Maximum [Member]
Quarterly Results Of Operations [Line Items]
Total Net Leverage Ratio	6
Q2 2016 to Q4 2016 [Member] | Minimum [Member]
Quarterly Results Of Operations [Line Items]
Total Net Leverage Ratio	1
Q1 2017 to Q2 2017 [Member] | Maximum [Member]
Quarterly Results Of Operations [Line Items]
Total Net Leverage Ratio	5.50
Q1 2017 to Q2 2017 [Member] | Minimum [Member]
Quarterly Results Of Operations [Line Items]
Total Net Leverage Ratio	1
Thereafter [Member] | Maximum [Member]
Quarterly Results Of Operations [Line Items]
Total Net Leverage Ratio	5
Thereafter [Member] | Minimum [Member]
Quarterly Results Of Operations [Line Items]
Total Net Leverage Ratio	1

Stockholder's Equity - Addition

Stockholder's Equity - Additional information (Detail) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Equity [Abstract]
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, par value	$ 0.01	$ 0.01

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term			10 years
Weighted average grant-date fair value of options granted	$ 0.99	$ 5.65	$ 1.42	$ 5.84
Time Based Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares that may be issued pursuant to awards	2,190,320		2,190,320

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Assumptions used for Estimating Fair Value of Each Option Award on Date of Grant using Black-Scholes Valuation Model (Detail) - Stock Options [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0.00%	0.00%	0.00%	0.00%
Risk-free interest rate, minimum	1.30%	1.60%	1.30%	1.50%
Risk-free interest rate, maximum	1.90%	1.90%	1.90%	1.90%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	26.00%	33.00%	26.00%	33.00%
Expected life (in years)	4 years 1 month 6 days	5 years 6 months	4 years 1 month 6 days	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	28.00%	35.00%	32.00%	35.00%
Expected life (in years)	6 years	6 years 3 months 18 days	6 years 3 months 18 days	6 years 3 months 18 days

Stock-Based Compensation - Sc59

Stock-Based Compensation - Schedule of Option Activity (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, beginning balance	1,531,110
Options granted	274,481
Options cancelled	(28,348)
Options exercised	0
Options forfeited or expired	(100,278)
Options Outstanding, ending balance	1,676,965	1,531,110
Vested and expected to vest	1,598,049
Exercisable	923,437
Options Outstanding, beginning balance, Weighted Average Exercise Price	$ 13.57
Options granted, Weighted Average Exercise Price	12.24
Options cancelled, Weighted Average Exercise Price	21.48
Options exercised, Weighted Average Exercise Price	0
Options forfeited or expired, Weighted Average Exercise Price	19.76
Options Outstanding, ending balance, Weighted Average Exercise Price	12.84	$ 13.57
Vested and expected to vest, Weighted Average Exercise Price	12.18
Exercisable, Weighted Average Exercise Price	$ 10.60
Options Outstanding, Weighted Average Remaining Contractual Term	5 years 8 months 12 days	6 years 4 months 24 days
Vested and expected to vest, Weighted Average Remaining Contractual Term	5 years 7 months 6 days
Exercisable, Weighted Average Remaining Contractual Term	4 years 6 months
Options Outstanding, Aggregate Intrinsic Value	$ 391,000	$ 3,979,000
Vested and expected to vest, Aggregate Intrinsic Value	383,000
Exercisable, Aggregate Intrinsic Value	$ 333,000
Time Based Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, beginning balance	1,146,509
Options granted	274,481
Options cancelled	(24,444)
Options exercised	0
Options forfeited or expired	(45,509)
Options Outstanding, ending balance	1,351,037	1,146,509
Vested and expected to vest	1,286,400
Exercisable	714,180
Performance Based Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, beginning balance	384,601
Options cancelled	(3,904)
Options exercised	0
Options forfeited or expired	(54,769)
Options Outstanding, ending balance	325,928	384,601
Vested and expected to vest	311,649
Exercisable	209,257

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Restricted Stock Awards Activity (Detail) - 6 months ended Jun. 30, 2015 - Restricted Stock [Member] - $ / shares	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time Based, issued and unvested beginning balance	0
Time Based, granted	479,708
Time Based, vested	0
Time Based, forfeited	(2,846)
Time Based, issued and unvested ending balance	476,862
Weighted Average Grant Date Fair Value, issued and unvested beginning balance	$ 0
Weighted Average Grant Date Fair Value, granted	8.34
Weighted Average Grant Date Fair Value, vested	0
Weighted Average Grant Date Fair Value, forfeited	8.52
Weighted Average Grant Date Fair Value, issued and unvested ending balance	$ 8.34

Stock-Based Compensation - Sc61

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 656	$ 251	$ 933	$ 535
Cost of Goods Sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	52	31	51	72
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	465	154	679	323
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	79	37	115	81
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 60	$ 29	$ 88	$ 59

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Earnings Per Share [Abstract]
Net loss	$ (24,423)	$ (1,636)	$ (24,048)	$ (2,921)	$ (3,561)
Basic and diluted weighted average common shares outstanding	18,898,003	18,080,944	18,489,451	18,080,256
Basic and diluted loss per common share	$ (1.29)	$ (0.09)	$ (1.30)	$ (0.16)

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock Options [Member] | Unvested Restricted Stock [Member]
Earnings Per Share [Line Items]
Weighted average number of common shares excluded from computation of earning per share	2,153,827	1,377,523	2,153,827	1,377,523

Other Expense, Net - Schedule o

Other Expense, Net - Schedule of Other Expense, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Other Income and Expenses [Abstract]
Foreign currency (losses) gains	$ 18	$ (154)	$ (360)	$ (392)
Tax indemnification (loss) income	781	(22)	777	(197)
Other income	1	1
Total other income (expense), net	$ 800	$ (175)	$ 417	$ (589)

Legal Proceedings and Conting65

Legal Proceedings and Contingencies - Additional Information (Detail)	Dec. 16, 2010Lawsuits
Claim Against Insurance Carriers to Recover Business Interruption Losses [Member]
Gain Contingencies [Line Items]
Number of suits filed	1

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Dec. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Avista [Member] | Advisory Services and Monitoring Agreement [Member]
Related Party Transaction [Line Items]
Annual fee		$ 1,000,000		$ 1,000,000
Costs incurred associated with agreement		6,800,000	$ 300,000	$ 7,000,000	$ 500,000
Purchases included in accrued expenses	$ 10,000
Agreement term				7 years
Aggregate termination fee paid				$ 6,500,000
Due from parent		0		0
VWR [Member]
Related Party Transaction [Line Items]
Expected payment to related party		44,000	$ 74,000	115,000	134,000
VWR [Member] | Accounts Payable and Accrued Liabilities [Member]
Related Party Transaction [Line Items]
Expected payment to related party	21,000			1,000
Marsh [Member]
Related Party Transaction [Line Items]
Expected payment to related party				100,000	$ 100,000
Prepaid expense due to related party in other current assets	$ 43,000	$ 43,000		$ 43,000

Segment Information - Additiona

Segment Information - Additional Information (Detail) - Segment	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Number of operating segments			2
Geographic Concentration Risk [Member] | U.S. [Member] | Revenues [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage	79.60%	77.50%	80.40%	77.50%
Geographic Concentration Risk [Member] | U.S. [Member] | Consolidated Assets [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage			89.80%		90.10%

Segment Information - Schedule

Segment Information - Schedule of Selected Information for Each Business Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Revenues
Revenues	$ 73,314	$ 75,613	$ 148,137	$ 148,949
Operating income
Operating income	5,356	9,980	16,734	18,469
Interest expense, net	(13,876)	(10,567)	(24,499)	(21,119)
Loss on extinguishment of debt	(15,528)		(15,528)
Other income (expense), net	800	(175)	417	(589)
Income (loss) before income taxes	(23,248)	(762)	(22,876)	(3,239)
Total assets
Assets	233,550		233,550		$ 243,153
U.S. [Member]
Revenues
Revenues	58,378	58,568	119,045	115,379
Total assets
Assets	209,665		209,665		219,129
International [Member]
Revenues
Revenues	14,936	17,045	29,092	33,570
Total assets
Assets	23,885		23,885		$ 24,024
Operating Segments [Member]
Revenues
Revenues	79,625	80,026	159,569	157,938
Operating income
Operating income	5,501	9,762	16,706	18,081
Operating Segments [Member] | U.S. [Member]
Revenues
Revenues	64,689	62,981	130,477	124,368
Operating income
Operating income	3,442	8,417	16,121	15,437
Operating Segments [Member] | International [Member]
Revenues
Revenues	14,936	17,045	29,092	33,570
Operating income
Operating income	2,059	1,345	585	2,644
Inter-Segment [Member]
Revenues
Revenues	(6,311)	(4,413)	(11,432)	(8,989)
Operating income
Operating income	$ (145)	$ 218	$ 28	$ 388